Tuin family exerts essential 58-49-1 functions in processes related to metabolism, such as aging and carcinogenesis [9,33]. Out of seven members of sirtuin family, SIRT3 has been drawing particular attentions with regard to its impacts on mitochondrial function. To date, data suggest SIRT3 520-26-3 exhibits dichotomous functions dependent on cell contexts: either as tumor promoter or as tumor suppressor [34]. On one hand, SIRT3 plays a role of tumor promoter. SIRT3 prevented bladder cancer cells from growth arrest and senescence by targeting p53 to inhibit its activity [35]. SIRT3 abrogated stress-mediated apoptosis by deacetylating Ku70 which resulted in enhancement of Ku70-Bax interaction and prevention of Bax translocation to mitochondria [36]. Furthermore, downregulation of SIRT3 arrested OSCC cell proliferation and sensitized cancer cells to radiation and chemotherapy treatments [18]. On the other hand, SIRT3 functions as a tumor repressor. It has been reported that 22948146 SIRT3 was required for JNK2-regulated apoptosis induced by selective silencing of Bcl-2 in HCT116 cells [37]. SIRT3 decreased ROS and maintained genomic stability to act as a tumor suppressor [38,39]. Furthermore, MEFs with Sirt32/2 were easilySIRT3 as a Prognostic Biomarker in HCCTable 2. Univariate analysis of SIRT3 expression and clinicopathologic variables in 248 patients with primary hepatocellular carcinoma (log-rank test).VariableAll casesOverall survival (months) Mean MedianRecurrence-free survival (months)P value0.MeanMedianP value0.Age (years) ,47.8 47.8 Gender Female Male HBsAg Positive Negativea13049.0 48.38.0 
40.0 0.42.8 43.29.0 38.0 0.2852.5 48.NR 38.0 0.34.6 44.35.0 42.0 0.21549.5 44.38.0 38.0 0.43.1 47.32.0 42.0 0.AFP (ng/ml) ,20 20 Cirrhosis Yes No Tumor size (cm) ,5 5 Tumor multiplicity Single Multiple Differentiation Well-Moderate Poor- Undifferentiation Stage I I III V Vascular invasion Yes No Relapse Yes No SIRT3 Low expression High expression 167 81 40.9 65.0 28.0 NR 101 147 31.1 64.2 24.0 NR 73 175 26.8 58.2 18.0 NR 109 139 70.9 33.4 NR 21.0 150 98 54.6 41.0 NR 26.0 131 117 62.6 35.3 NR 24.0 121 127 59.1 40.8 NR 27.0 180 68 48.2 51.7 36.0 NR 102 146 65.8 37.7 NR 27.52.9 36.1 0.500 42.1 47.6 0.000 53.4 35.3 0.000 49.8 36.7 0.003 47.7 36.4 0.000 61.7 31.0 0.000 18.5 57.9 0.57.0 25.0 0.529 30.0 42.0 0.000 74.0 22.0 0.008 42.0 26.0 0.024 42.0 26.0 0.000 NR 22.0 0.000 15.0 NR0.000 37.4 53.5 28.0 NR0.a Mean age; NR, not reached; HbsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein. doi:10.1371/journal.pone.0051703.timmortalized by infection with a single oncogene, and developed into subcutaneous xenograft tumor in nude mice once expressing Myc or Ras [17]. Moreover, SIRT3 deficiency in over one-year old mice resulted in development of estrogen- and progesteronepositive mammary tumors [17]. More recently, SIRT3 was shown to downreguated MDM2 to prevent p53 degradation, which subsequently inhibited HCC cell growth [19]. In our study, SIRT3 was dramatically decreased in HCC cell lines and more than 200 HCC tissue samples, at both mRNA and protein levels. Further data demonstrated that poorly-differentiated tumors expressed lessSIRT3 than well-differentiated tumors in most of HCC cases. Moreover, low SIRT3 expression was positively significantly correlated to advanced clinical stage, high serum AFP, multiple tumor numbers and higher relapse rate. Collectively, these data indicated loss of SIRT3 was coincident with tumor progression, which suggests SIRT3 as a tumor.Tuin family exerts essential functions in processes related to metabolism, such as aging and carcinogenesis [9,33]. Out of seven members of sirtuin family, SIRT3 has been drawing particular attentions with regard to its impacts on mitochondrial function. To date, data suggest SIRT3 exhibits dichotomous functions dependent on cell contexts: either as tumor promoter or as tumor suppressor [34]. On one hand, SIRT3 plays a role of tumor promoter. SIRT3 prevented bladder cancer cells from growth arrest and senescence by targeting p53 to inhibit its activity [35]. SIRT3 abrogated stress-mediated apoptosis by deacetylating Ku70 which resulted in enhancement of Ku70-Bax interaction and prevention of Bax translocation to mitochondria [36]. Furthermore, downregulation of SIRT3 arrested OSCC cell proliferation and sensitized cancer cells to radiation and chemotherapy treatments [18]. On the other hand, SIRT3 functions as a tumor repressor. It has been reported that 22948146 SIRT3 was required for JNK2-regulated apoptosis induced by selective silencing of Bcl-2 in HCT116 cells [37]. SIRT3 decreased ROS and maintained genomic stability to act as a tumor suppressor [38,39]. Furthermore, MEFs with Sirt32/2 were easilySIRT3 as a Prognostic Biomarker in HCCTable 2. Univariate analysis of SIRT3 expression and clinicopathologic variables in 248 patients with primary hepatocellular carcinoma (log-rank test).VariableAll casesOverall survival (months) Mean MedianRecurrence-free survival (months)P value0.MeanMedianP value0.Age (years) ,47.8 47.8 Gender Female Male HBsAg Positive Negativea13049.0 48.38.0 40.0 0.42.8 43.29.0 38.0 0.2852.5 48.NR 38.0 0.34.6 44.35.0 42.0 0.21549.5 44.38.0 38.0 0.43.1 47.32.0 42.0 0.AFP (ng/ml) ,20 20 Cirrhosis Yes No Tumor size (cm) ,5 5 Tumor multiplicity Single Multiple Differentiation Well-Moderate Poor- Undifferentiation Stage I I III V Vascular invasion Yes No Relapse Yes No SIRT3 Low expression High expression 167 81 40.9 65.0 28.0 NR 101 147 31.1 64.2 24.0 NR 73 175 26.8 58.2 18.0 NR 109 139 70.9 33.4 NR 21.0 150 98 54.6 41.0 NR 26.0 131 117 62.6 35.3 NR 24.0 121 127 59.1 40.8 NR 27.0 180 68 48.2 51.7 36.0 NR 102 146 65.8 37.7 NR 27.52.9 36.1 0.500 42.1 47.6 0.000 53.4 35.3 0.000 49.8 36.7 0.003 47.7 36.4 0.000 61.7 31.0 0.000 18.5 57.9 0.57.0 25.0 0.529 30.0 42.0 0.000 74.0 22.0 0.008 42.0 26.0 0.024 42.0 26.0 0.000 NR 22.0 0.000 15.0 NR0.000 37.4 53.5 28.0 NR0.a Mean age; NR, not reached; HbsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein. doi:10.1371/journal.pone.0051703.timmortalized by infection with a single oncogene, and developed into subcutaneous xenograft tumor in nude mice once expressing Myc or Ras [17]. Moreover, SIRT3 deficiency in over one-year old mice resulted in development of estrogen- and progesteronepositive mammary tumors [17]. More recently, 
SIRT3 was shown to downreguated MDM2 to prevent p53 degradation, which subsequently inhibited HCC cell growth [19]. In our study, SIRT3 was dramatically decreased in HCC cell lines and more than 200 HCC tissue samples, at both mRNA and protein levels. Further data demonstrated that poorly-differentiated tumors expressed lessSIRT3 than well-differentiated tumors in most of HCC cases. Moreover, low SIRT3 expression was positively significantly correlated to advanced clinical stage, high serum AFP, multiple tumor numbers and higher relapse rate. Collectively, these data indicated loss of SIRT3 was coincident with tumor progression, which suggests SIRT3 as a tumor.
